Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik, Andres; Foley, Bree; Zhang, Bin; Verneris, Michael R; Warlick, Erica; Gleason, Michelle K; Ross, Julie A; Luo, Xianghua; Weisdorf, Daniel J; Walcheck, Bruce; Vallera, Daniel A; Miller, Jeffrey S.
Clin Cancer Res
; 19(14): 3844-55, 2013 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-23690482
How One Thing Led to Another.
CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML.
Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia.
CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.
The origin and evolution of mutations in acute myeloid leukemia.
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Lifting the Differentiation Embargo.
A 17-gene stemness score for rapid determination of risk in acute leukaemia.